Myasthenia Gravis Disease Market

The Myasthenia Gravis (MG) market encompasses treatments for a chronic autoimmune disorder that causes skeletal muscle weakness. The primary customers are patients with MG who are treated within hospital and clinic settings. Key growth drivers include the increasing global prevalence of the disease, advancements in diagnostic techniques, and the development and approval of more effective treatments such as biologic therapies and personalized medicine.